首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

亞太地區T 細胞治療市場預測至2030 年- 區域分析- 按模式（研究和商業化）、治療類型[CAR T 細胞療法和基於T 細胞受體(TCR) 的] 和適應症（血液惡性腫瘤和實體瘤）

市場調查報告書

商品編碼

1452623

亞太地區T 細胞治療市場預測至2030 年- 區域分析- 按模式（研究和商業化）、治療類型[CAR T 細胞療法和基於T 細胞受體(TCR) 的] 和適應症（血液惡性腫瘤和實體瘤）

Asia Pacific T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

出版日期: 2024年01月15日 | 出版商:

The Insight Partners | 英文 76 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2022年亞太地區T細胞治療市場估值為2.5199億美元，預計2030年將達8.8272億美元；預計2022年至2030年CAGR為17.0%。

T 細胞治療核准數量的增加推動了亞太地區 T 細胞治療市場的發展

標靶治療、更快、更有效的恢復以及減少副作用都是 T 細胞療法的優點。在全球範圍內，由於獲得了各種批准，細胞療法被廣泛採用。例如，2023年：楊森的CAR-T細胞療法CARVYKTI（Ciltacabtagene Autoleucel）已被澳洲治療產品管理局批准作為多發性骨髓瘤患者的四線治療。

2023年：中國國家藥品監督管理局核准信達生物及IASO生物技術公司（IASO Bio）的Fucaso（equecabtagene autoleucel）用於治療成人復發或難治性多發性骨髓瘤（RRMM）患者。 2023年6月，該機構批准了該療法的新藥申請（NDA）。

2023年：第一個人源化CD19靶向嵌合抗原受體T細胞（CAR-T細胞）治療產品NexCAR19（Actalycabtagene autoleucel）已獲得中央藥品標準控制組織（CDSO）批准用於治療復發/難治性癌症印度的 B 細胞淋巴瘤和白血病。免疫過繼性細胞療法在印度理工學院孟買分校孵化。

2023年：復星凱特生物科技研發的自體CAR T細胞療法益凱達（axicabtagene ciloleucel）獲得中國國家藥品監督管理局（NMPA）批准用於大B細胞淋巴瘤患者的二線治療。

2020 年：日本厚生勞動省 (MHLW) 向神戶生物醫學研究與創新基金會 (“FBRI”) 授予行銷許可證，為日本患者生產和分銷 Kymriah (tisagenlecleucel)。諾華公司今天宣布了這項消息。憑藉這項許可，FBRI 現在成為亞洲唯一授權的 CAR-T 細胞療法商業生產工廠。

因此，越來越多的 T 細胞療法獲批正在推動市場成長。

亞太地區T細胞治療市場概況

亞太地區 T 細胞治療市場分為中國、日本、印度、韓國、澳洲和亞太其他地區。由於 CAR T 細胞療法可有效治療癌症，從而推動該地區的市場成長，預計亞太地區市場將顯著成長。該地區正在進行許多 CAR T 細胞療法的臨床試驗，這為亞太地區提供了新的機會。中國是全球開展CAR T細胞臨床試驗最多的國家，醫院進行的臨床試驗也最多。中國正在形成 CAR-T 產業鏈，包括正在進行和預期的監管改革，以有利於獲得此類新療法。中國於2021 年9 月批准了JW Therapeutics 的首個CAR T 細胞療法relmacabtagene autoleucel，用於治療經過兩種或多種全身治療後的複發或難治性大B 細胞淋巴瘤(r/r LBCL) 成人患者。

亞太地區 T 細胞治療市場收入及 2030 年預測（百萬美元）

亞太地區T細胞治療市場區隔

亞太地區 T 細胞治療市場分為模式、治療類型、適應症和國家。

根據模式，亞太 T 細胞治療市場分為研究和商業化。 2022年，商業化細分市場將佔據更大的市場佔有率。

根據治療類型，亞太地區T細胞治療市場分為CAR T細胞療法和T細胞受體（TCR）療法。 2022年，CAR T細胞療法領域將佔據更大的市場佔有率。

根據適應症，亞太地區 T 細胞治療市場分為血液惡性腫瘤和實體腫瘤。 2022 年，血液惡性腫瘤細分市場佔據最大市場。

依國家/地區分類，亞太地區 T 細胞治療市場分為中國、日本、澳洲、韓國和亞太地區其他地區。 2022年，中國在亞太T細胞治療市場佔據主導地位。

百時美施貴寶公司、吉利德科學公司、信達生物製品公司、楊森全球服務有限責任公司、JW（開曼）治療有限公司、傳奇生物科技公司和諾華公司是亞太地區T 細胞治療市場上的一些領先公司。

Targeted treatment, faster and more efficient recovery, and reduced side effects are among the advantages of t cell therapy. Globally, cell therapies are widely adopted owing to the availability of various approvals. For instance, in 2023: Janssen's CAR-T cell therapy CARVYKTI (Ciltacabtagene Autoleucel) has been approved as a fourth-line treatment for multiple myeloma patients by the Therapeutic Goods Administration, Australia.

In 2023: The Chinese National Medical Products Administration has approved the use of Fucaso (equecabtagene autoleucel) by Innovent Biologics and IASO Biotechnology (IASO Bio) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). In June 2023, the agency approved the therapy's new drug application (NDA).

In 2023: The first humanized CD19-targeted Chimeric Antigen Receptor T cell (CAR-T cell) therapy product, NexCAR19 (Actalycabtagene autoleucel), has been approved by the Central Drugs Standard Control Organization (CDSO) for use in cases of relapsed/refractory B-cell lymphomas and leukemia in India. Immuno Adoptive Cell Therapy is incubated at IIT Bombay.

In 2023: Yikaida (axicabtagene ciloleucel), an autologous CAR T-cell therapy developed by Fosun Kite Biotechnology, was granted approval by China's National Medical Products Administration (NMPA) for use as a second-line treatment for patients with large B-cell lymphoma.

In 2020: The Ministry of Health, Labor and Welfare (MHLW) of Japan has granted the Foundation for Biomedical Research and Innovation at Kobe ("FBRI") a marketing license to produce and distribute Kymriah (tisagenlecleucel) for patients in Japan. Novartis made this announcement today. With this clearance, FBRI is now the only authorized commercial manufacturing facility in Asia for CAR-T cell therapy.

Thus, the increasing number of approvals for T-cell therapy is fueling the market growth.

Asia Pacific T Cell Therapy Market Overview

The Asia Pacific T-cell therapy market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market in Asia Pacific is expected to witness significant growth as CAR T-cell therapy is efficient in treating cancer, elevating the market growth in the region. Many clinical trials for CAR T-cell therapy are ongoing in the region, offering new opportunities in APAC. China is the largest country in the world for CAR T-cell clinical trials, which hospitals conduct. The CAR-T industry chain is being formed in China, including ongoing and expected regulatory reforms to benefit access to such novel therapies. China approved its first CAR T-cell therapy, relmacabtagene autoleucel of JW Therapeutics, in September 2021 for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy.

Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)

Asia Pacific T Cell Therapy Market Segmentation

The Asia Pacific T cell therapy market is segmented into modality , therapy type, indication, and country.

Based on modality, the Asia Pacific T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the Asia Pacific T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the Asia Pacific T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the Asia Pacific T cell therapy market is segmented into China, Japan, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific T cell therapy market in 2022.

Bristol-Myers Squibb Co, Gilead Sciences Inc, Innovent Biologics Inc, Janssen Global Services LLC, JW (Cayman) Therapeutics Co Ltd, Legend Biotech Corp, and Novartis AG are some of the leading companies operating in the Asia Pacific T cell therapy market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Asia Pacific T Cell Therapy Market, by Country (US$ Million)

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific T Cell Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Growing Burden of Cancer Worldwide
- 4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
- 4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
- 4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
- 4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:

5. T Cell Therapy Market - Asia Pacific Market Analysis

5.1 Asia Pacific T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

6. Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality.

6.1 Overview
6.2 Asia Pacific T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
- 6.3.1 Overview
- 6.3.2 Research: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
- 6.4.1 Overview
- 6.4.2 Commercialized: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

7.1 Overview
7.2 Asia Pacific T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
- 7.3.1 Overview
- 7.3.2 CAR T-cell Therapy: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
- 7.4.1 Overview
- 7.4.2 T-cell Receptor (TCR)-based: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication.

8.1 Overview
8.2 Asia Pacific T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
- 8.3.1 Overview
- 8.3.2 Hematologic Malignancies: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3.3 Asia Pacific T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
- 8.4.1 Overview
- 8.4.2 Solid Tumor: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific T Cell Therapy Market - Country Analysis

9.1 Overview

10. T Cell Therapy Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Legend Biotech Corp
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Janssen Global Services LLC
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Gilead Sciences Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Bristol-Myers Squibb Co
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Novartis AG
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 JW (Cayman) Therapeutics Co Ltd
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Innovent Biologics Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. Asia Pacific T Cell Therapy Market Segmentation
Table 2. Asia Pacific T Cell Therapy Market, by Hematological Malignancies - Revenue and Forecast to 2030 (US$ Million)
Table 3. FDA-Approved Autologous CAR T-Cell Therapies Registered in Asia Pacific
Table 4. China: Asia Pacific T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 5. China: Asia Pacific T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 6. China: Asia Pacific T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 7. China: Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 8. Japan: Asia Pacific T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 9. Japan: Asia Pacific T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 10. Japan: Asia Pacific T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 11. Japan: Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 12. Australia: Asia Pacific T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 13. Australia: Asia Pacific T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 14. Australia: Asia Pacific T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 15. Australia: Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 16. South Korea: Asia Pacific T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 17. South Korea: Asia Pacific T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 18. South Korea: Asia Pacific T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 19. South Korea: Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 20. Rest of Asia Pacific: Asia Pacific T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 21. Rest of Asia Pacific: Asia Pacific T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 22. Rest of Asia Pacific: Asia Pacific T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Asia Pacific: Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 24. Recent Organic Growth Strategies in Asia Pacific T Cell Therapy Market
Table 25. Recent Inorganic Growth Strategies in the Asia Pacific T Cell Therapy Market
Table 26. Glossary of Terms, Asia Pacific T Cell Therapy Market

List Of Figures

Figure 1. Asia Pacific T Cell Therapy Market Segmentation, By Country
Figure 2. Asia Pacific T Cell Therapy Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
Figure 5. Asia Pacific T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
Figure 6. Research: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Commercialized: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Asia Pacific T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
Figure 9. CAR T-cell Therapy: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. T-cell Receptor (TCR)-based: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Asia Pacific T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 12. Hematologic Malignancies: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Solid Tumor: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Asia Pacific T Cell Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
Figure 15. Asia Pacific T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 16. China: Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. Japan: Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 18. Australia: Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. South Korea: Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. Rest of Asia Pacific: Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Growth Strategies in T Cell Therapy Market